

The NCATS Pharmaceutical Collection: Potential Use for Rapid Repurposing Against New/Emerging Threats




Anton Simeonov, Ph.D.
Division of Preclinical Innovation
National Center for Advancing Translational Sciences (NCATS)
National Institutes of Health



*BARDA Industry Day, Washington, DC
December 10, 2012*




The NCATS Division of Preclinical Innovation: An Integrated Pipeline




Range of screening assays performed

Extent of reductionism →


Phenotype
(Image-based HCS, GFP, etc)



Pathway
(Reporters, e.g., luciferase, β -lactamase)




Protein
(Enzyme readouts, interactions, etc)




Screening Formats

C




96-well plate

- 8 rows x 12 columns
- 88 test samples



384-well plate
4 x 96-well plates

- 16 rows x 32 columns
- 352 test samples





1536-well plate
16 x 96-well plates

- 32 rows x 48 columns
- 1,408 test samples

If @ 100 microtiter plates per day:

Plate format	samples\$/day (wells/day)	Time to screen 1 M samples
96-well	8,800 (9,600)	4 months
384-well	35,200 (38,400)	4 weeks
1536-well	140,800 (153,600)	7 days

Integrated Robotic Screening System



- All screens performed as multipoint titration series
- In total, ~500,000 compounds across multiple sub-libraries
- >250 collaborative projects with investigators worldwide


Automated concentration-response data collection for every sample tested

PNAS, 2006, **103**, 11473-11478
Assay Drug Dev. Technol., 2008, **6**, 637-658


HTS System in BSL-3 Facility, NIH Main Campus

Screen Preparation

Day Zero: Reagent Dispense and Incubation Start



Bldg. 33, CW Bill Young Center (NIAID)



Day 3: Plate Read




Plate stacker

Abgene plate sealer

Biomek NX Single arm: 96MC head


Anaerobic chamber with airlock

EnVision plate reader

Dual bed series nitrogen generator

13,000-compound collection screened in dose-response mode against *M. tuberculosis*

Two Approaches to Therapeutics




Enabling Comprehensive Drug Repurposing

The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics

Ruili Huang,* Noel Southall,* Yuhong Wang, Adam Yasgar, Paul Shinn,
Ajit Jadhav, Dac-Trung Nguyen, Christopher P. Austin[†]

Small-molecule compounds approved for use as drugs may be “repurposed” for new indications and studied to determine the mechanisms of their beneficial and adverse effects. A comprehensive collection of all small-molecule drugs approved for human use would be invaluable for systematic repurposing across human diseases, particularly for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous efforts to build such a comprehensive collection have been limited by the complexities, redundancies, and semantic inconsistencies of drug naming within and among regulatory agencies worldwide; a lack of clear conceptualization of what constitutes a drug; and a lack of access to physical samples. We report here the creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening.

Workflow for the NPC library construction process



The NCGC Pharmaceutical Collection - Windows - Internet Explorer

http://tripod.nih.gov/npc/

File Edit View Favorites Tools Help

The NCGC Pharmaceutical Collection

The NCGC Pharmaceutical Collection

current version 1.1.0

Home Siphonify Overview Screenshots Jobs About

Contents

- [What is the NCGC Pharmaceutical Collection \(NPC\)?](#)
- [How do I get access to the NPC?](#)
- [How do I download the NPC Browser?](#)
- [What's in the NPC browser?](#)
- [How reliable are the compound records in the NPC browser?](#)
- [How can I build my own NPC physical collection?](#)
- [Has the NPC screening library been characterized analytically?](#)
- [How do I cite the NPC resource?](#)
- [Contact](#)
- [Acknowledgements](#)

What is the NCGC Pharmaceutical Collection (NPC)?

The NCGC Pharmaceutical Collection (NPC) is a comprehensive, publically-accessible collection of approved and investigational drugs for high-throughput screening that provides a valuable resource for both validating new models of disease and better understanding the molecular basis of disease pathology and intervention. The NPC has already generated several useful probes for studying a diverse cross section of biology, including novel targets and pathways. NCGC provides access to its set of approved drugs and bioactives through the [Therapeutics for Rare and Neglected Diseases](#) (TRND) program and as part of the compound collection for the [Tox21 initiative](#), a collaborative effort for toxicity screening among several government agencies including the US Environmental Protection Agency (EPA), the National Toxicology Program (NTP), the US Food and Drugs Administration (FDA), and the NCGC. Of the nearly 2750 small molecular entities (MEs) that have been approved for clinical use by US (FDA), EU (EMA), Japanese (NHI), and Canadian (HC) authorities and that are amenable to HTS screening, we currently possess 2400 as part of our screening collection.

How do I get access to the NPC?

The NPC resource currently consists of (i) the physical collection suitable for high throughput screening (HTS) and (ii) the informatics browser and database. Putting together the physical collection has been surprisingly challenging in terms of the time and effort required in the informatics, compound management and synthetic chemistry related activities required for this endeavor. We provide access to the NPC screening library through collaboration. Please contact our Scientific Director Dr. [Chris Austin](#) for additional information.

The other half of the NPC resource is the NPC browser. This is a self-contained software that is actively developed and maintained by the informatics group to provide electronic access to the NPC content. The latest version of the NPC browser for various platforms can be downloaded [below](#). Please let us know if your platform is not listed. Note that a fairly modern hardware (preferably with at least 2Gb of memory) is required to run the browser effectively.

How do I download the NPC browser?

File	Platform	Size	MD5 checksum
npc-browser_windows_1_1_0.exe	Windows	94.3 MB	9329911fba2e6ff44f2645f38337cc3b
npc-browser_macos_1_1_0.dmg	Mac OS X	78.7 MB	b9e58f73ba1f13a74f6525a2b88c7807
npc-browser_unix_1_1_0.sh	Linux	95.3 MB	7afedcc3741bd0ab8c96938a9ab9c852

Links

- [NCGC](#)
- [MLI](#)
- [NHGRI](#)
- [PubChem](#)
- [ClinicalTrials.gov](#)
- [DailyMed](#)
- [Drug Portal](#)

Presentations

- [ACS Spring 2010](#)
- [Chemaxon UGM 2008](#)

Tools

- [Automated R-group analysis](#)
- [Fragment activity profiler](#)
- [Kinome navigator](#)
- [Kinome viewer](#)
- [Molecular framework](#)
- [MolSubspace](#)
- [Multiple MCS](#)
- [Scaffold activity diagram](#)
- [Siphonify](#)
- [Structure standardizer](#)
- [Tautomer generator](#)
- [The NPC browser](#)

Recent Posts

- [Large scale substructure searching](#)
- [MLBD browser](#)
- [On faster substructure searching](#)
- [Siphonify](#)
- [NPC paper](#)

Local intranet 100%

<http://tripod.nih.gov/npc/>

Procurement Sources




Supplier Name	Supplier Type
Advanced Technology & Industrial Co., Ltd	Specialty Chemicals
AKos Consulting and Solutions GmbH	Specialty Chemicals
Apin	Specialty Chemicals
Apollo Scientific Ltd	Specialty Chemicals
ART-CHEM GmbH	Specialty Chemicals
ASDI Inc.	Specialty Chemicals
Aurora Fine Chemicals	Specialty Chemicals
Beta Pharma Inc	Specialty Chemicals
BioAustralis	Specialty Chemicals
Bionet Research (Owned by Key Organics)	Specialty Chemicals
BIOTREND Chemicals AG	Specialty Chemicals
Bosche Scientific, LLC	Specialty Chemicals
Chemical Block Ltd.	Specialty Chemicals
Chemos	Specialty Chemicals
ChemPacific Corp.	Specialty Chemicals
ChemSampCo	Specialty Chemicals
CHESS	Specialty Chemicals
CiVentiChem	Specialty Chemicals
Epsilon Chimie	Specialty Chemicals
HuskerChem	Specialty Chemicals
INDOFINE Chemical Company, Inc	Specialty Chemicals
Kemprotec Limited	Specialty Chemicals
Labotest	Specialty Chemicals
LKT Laboratories, Inc	Specialty Chemicals
Matrix Scientific	Specialty Chemicals
MDD World Molecules	Specialty Chemicals
Menal Organics	Specialty Chemicals
Molecular Diversity Preservation Intl.	Specialty Chemicals
National Cancer Institute	Specialty Chemicals
Oakwood Product, Inc.	Specialty Chemicals
Peakdale Molecular Ltd	Specialty Chemicals
Pharmeks LTD.	Specialty Chemicals
PolyPeptide Group (formerly NeoSystem SA)	Specialty Chemicals
Scientific Exchange	Specialty Chemicals
Selleck	Specialty Chemicals
Sequoia Research Product LTD	Specialty Chemicals
SynphaBase AG	Specialty Chemicals
Tripos	Specialty Chemicals
Tyger Scientific, Inc	Specialty Chemicals
Vitas-M Laboratory Ltd.	Specialty Chemicals


Supplier Name	Supplier Type
Alfa Aesar	Bulk Chemicals
Asinex Ltd.	Bulk Chemicals
CalBioChem	Bulk Chemicals
ChemBridge Corporation	Bulk Chemicals
ChemDiv, Inc	Bulk Chemicals
Enamine	Bulk Chemicals
Innovapharm Ltd.	Bulk Chemicals
InterBioScreen Ltd.	Bulk Chemicals
Maybridge	Bulk Chemicals
SigmaAldrich - ALDRICH	Bulk Chemicals
SigmaAldrich - FLUKA	Bulk Chemicals
SigmaAldrich - RIEDEL	Bulk Chemicals
SigmaAldrich - SALOR	Bulk Chemicals
SigmaAldrich - SIGMA	Bulk Chemicals
SigmaAldrich - Sigma DiscoveryCPR	Bulk Chemicals
Specs	Bulk Chemicals
Tocris Bioscience	Bulk Chemicals
American Custom Chemicals Corporation	Custom Synthesis
APAC Pharmaceutical, LLC	Custom Synthesis
Florida Center for Heterocyclic Compounds	Custom Synthesis
GVK Biosciences	Custom Synthesis
NIH Center for Chemical Genomics	Custom Synthesis
Pharmaron	Custom Synthesis
University of Pittsburgh UPCMLD	Custom Synthesis
Henry Schein	Pharmacies
National Institute on Drug Abuse	Pharmacies
United States Pharmacopeial Convention, Inc.	Pharmacies
Walter Reed	Pharmacies
Ambinter	Screening Libraries
BIOMOL	Screening Libraries
Microsource	Screening Libraries
Prestwick	Screening Libraries
SigmaAldrich - LOPAC	Screening Libraries
Tim Tec, Inc	Screening Libraries
Toronto Research Chemicals	Screening Libraries




The NPC Screening Resource



Composition



Sources



Cost

NPC Status, 2012

<i>Drug Source</i>	<i>In house</i>	<i>Procurement in process</i>
US FDA	1635	182
UK/EU/Canada/Japan	756	177
Investigational	928	3953
Total Approved	2391	359
Total	3319	4312

Repurposing Case Study: Refractory CLL

CLL – Chronic Lymphocytic Leukemia

- 30% of all leukemias
- Standard of care: chemotherapy

Relapse virtually universal; treatments needed for refractory disease

NPC CLL screen

- CLL and normal donor B-cells obtained from patients at NIH Clinical Center
 - Adrian Wiestner, NHLBI
 - Cells from six CLL patients and five normal donors tested

- NPC screened at 9 concentrations, 1 nM to 57 μ M
 - Readout: cell viability (ATP measurement)

Desired compound profile = *Differential* cell killing



KUMC News

[KUMC Home](#) > [News Listing Page](#) > [KU researchers repurpose arthritis drug to treat leukemia](#)

Search KUMC news:

×

KU's Institute for Advancing Medical Innovation, The Leukemia & Lymphoma Society and NIH begin groundbreaking clinical trial for leukemia patients

November 01, 2011

By KUMC News

As part of an aggressive effort to speed delivery of treatments to patients by finding new uses for approved drugs, researchers at the University of Kansas Medical Center have begun a clinical trial targeting the most common form of adult leukemia with a drug first approved to treat arthritis more than 25 years ago.

Earlier this month, KU researchers treated the first trial participant, a Kansas City-area patient suffering from chronic lymphocytic leukemia or CLL, with the drug auranofin, which has long been used to treat patients with arthritis.

The trial is one key piece of a larger collaboration between KU, The Leukemia & Lymphoma Society (LLS) and the National Institutes of Health (NIH) to accelerate discovery and development of safe, effective and affordable cancer treatments. Over the last two years, the group discovered that auranofin kills CLL cells in test tubes, and received approval to test the drug in CLL patients.


"Today's process of discovering and developing new drugs for patients takes too much time and costs too much money," said Louis J. DeGennaro, Ph.D., executive vice president and chief mission officer, LLS. "The collaboration between KU, LLS and NIH is committed to giving new hope to patients by reducing sharply the time and costs associated with developing new therapies. Auranofin is a great example of what is possible through an effective public-private partnership."

"Spending more than \$1 billion and taking more than a decade to deliver new therapies to patients is simply not sustainable," said Scott Weir, PharmD, PhD, director of KU's Institute for Advancing Medical Innovation. "Our group moved this new discovery into a clinical trial in just two years and for about \$1 million, representing significant time and cost savings from business as usual."





Scott Weir, PharmD, PhD, is director of KU's Institute for Advancing Medical Innovation

The NCATS Division of Preclinical Innovation: An Integrated Pipeline



The Tox21 Community




- Identify patterns of compound-induced biological response in order to:
 - Characterize toxicity/disease pathways
 - Prioritize compounds for more extensive toxicological evaluation
- Develop predictive models for biological response in humans, while minimizing use of laboratory animals

Tox21 Robot Ribbon-Cutting March 10, 2011



(L to R): Eric Green (Director, NHGRI/NIH), Linda Birnbaum (Director, NIEHS/NIH), Janet Woodcock (Director, CDER/FDA), Lek Kadelli (Asst Administrator, ORD/EPA)



Mobilization of Tox21 Team: BP Oil Spill

Environ. Sci. Technol. XXXX, xxx, 000–000

Analysis of Eight Oil Spill Dispersants Using Rapid, In Vitro Tests for Endocrine and Other Biological Activity

RICHARD S. JUDSON,^{*,†}
MATTHEW T. MARTIN,[†] DAVID M. REIF,[†]
KEITH A. HOUCK,[†]
THOMAS B. KNUDSEN,[†]
DANIEL M. ROTROFF,[†] MENGHANG XIA,[‡]
SRILATHA SAKAMURU,[‡] RUILI HUANG,[‡]
PAUL SHINN,[‡]
CHRISTOPHER P. AUSTIN,[‡]
ROBERT J. KAVLOCK,[†] AND
DAVID J. DIX[†]

National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, and NIH Chemical Genomics Center, National Institutes of Health, Department of Health and Human Services, Bethesda, Maryland 20892

Received June 25, 2010. Revised manuscript received June 30, 2010. Accepted June 30, 2010.

Energy Services, L.P., Sugar Land, TX). In excess of 1.5 M gallons of dispersant have been released into the Gulf as of June 26, 2010. Oil spill dispersants are complex mixtures of two basic components (1). The first component is composed of one or more surfactants that can emulsify oil. The second component is a hydrocarbon-based solvent mixture that helps break up large clumps of high molecular weight, more viscous oil. There is limited information on the potential of dispersants to cause acute or long-term toxicity in aquatic species or humans.

EPA's Office of Research and Development was asked to evaluate the potential toxicity of eight oil spill dispersants, including Corexit 9500. Because of the need for rapid turnaround, it was decided to employ a series of in vitro, cell-based assays. One mode of toxicity that is of concern for dispersants is endocrine disruption (2), due to the fact that nonylphenol ethoxylates (NPEs) are used in some of the dispersants as part of the surfactant component. NPEs can degrade to produce nonylphenol (3), which can strongly interact with the estrogen receptor (4–7). NPEs themselves have been shown to inhibit testicular growth in rainbow trout (8). Because of this fact, the focus of our in vitro studies was on measuring potential interaction of the dispersants with the estrogen receptor (ER) and the androgen receptor (AR).

Here we describe the results of a series of rapid in vitro tests to determine the interaction of eight oil spill dispersants with ER, AR, and other receptors and transcription factors.

The Tox21 team was called upon to perform rapid testing of oil dispersants used in the Gulf of Mexico BP oil spill: multiple cell lines revived and associated assays performed during the Memorial Day weekend.

Potential Utilization of the NPC for NETs

- Therapeutics for NETs must be identified rapidly
 - Timeline of NME development (10 yr) incompatible, making repurposing of currently approved drug only rapid route for NET (1-2 yr scale)
 - NCGC is NIH intramural facility so can be activated for national need with very little lead time (as done during the Gulf Oil Spill disaster)
 - NPC is comprehensive informatics and screening collection resource purpose-built for this type of need
- NCGC can screen entire NPC as 15-point dilution series in <1 wk, already >100 assays screened
 - BSL 1-2 at main facility, BSL 3 at NIH Bldg 33
- NPC not screened against NETs to date due to lack of mandate/funding for such activity, all current projects are funded for specific deliverables

Selected Infectious Disease Projects at the Center

- Anthrax internalization
- Botulinum NT (USAMRIID)
- *E. coli*: DNA replication modulators, Beta-lactamase, posttranslational modifications
- Giardia: Fructose-1,6-bisphosphate aldolase, trophozoite viability
- Lassa and Marburg VSV pseudotypes
- HIV nucleocapsid
- Hookworm TGR
- Influenza NS1
- Leishmania pyruvate kinase
- Malaria: Killing/profiling, Plastid replication, delayed-death phenotype
- SARS: Viral protease inhibitors
- Shigella: Toxin modulators
- Schistosomiasis: redox maintenance proteins
- Trypanosomiasis: Cruzain, TbPFK, LmPGAM and TbPGK
- Tuberculosis: Cell killing, profiling (BSL-3)
- Venezuelan equine encephalitis virus (VEEV) (USAMRIID)
- Vaccinia Virus Entry

Practical Issues in Utilizing the NPC for NETs

- Ongoing re-acquisition of collection (100 mg) very expensive so taking some time
 - Total cost >\$7M
- To conserve drug, all screening done in-house, we do not send copies of collection except in very exceptional circumstances
 - We utilize only 20 nl -100 nl of compound for each test well
- We cannot do BSL4 screens

Summary

- Repurposing collection and screening capacity in place, could be used for NETs
- NCATS-DPI would be very interested in working with our Federal partners on this
 - Tox21 is very productive precedent
 - NPC unique to NCGC
 - qHTS unique to NCGC
 - Intramural Federal lab status makes project like this very flexible
- The project would require resources but marginal cost to BARDA and partners would be small as much of investment in collection and assay/screening/informatics capacity already made

Further Information

NATIONAL INSTITUTES OF HEALTH NIH...Turning Discovery Into Health

Search

NCATS National Center for Advancing Translational Sciences

Research

Funding & Notices

News & Events


Policy Issues

About NCATS

DISCOVERING NEW THERAPEUTIC USES FOR EXISTING MOLECULES

NCATS unveils new program that matches researchers with more than 20 pharmaceutical industry compounds to help scientists explore new treatments for patients.

1 2 3 4



RESEARCH HIGHLIGHTS

Clinical and Translational Science

Learn more about clinical and translational science activities at NCATS.

Rare Disease Research and Therapeutics

Learn more about rare disease research and therapeutics efforts at NCATS.

Re-engineering Translational Sciences

Preclinical translational research is the bridge between basic research and human medicine.

NCATS.nih.gov

asimeono@mail.nih.gov